XXII News and Press, 22nd Century Group Inc From 03/02/23

BUFFALO, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that the Company will be participati...

BUFFALO, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, will host a live webcast on Thursday, March 9, 2023, ...

22nd Century Group ( NASDAQ: XXII ) has accelerated a seed cultivation designed to produce tobacco with reduced nicotine content. The program comes as a New Zealand law comes into effect that mandates lower nicotine content. The company said that its reduced nicotine tobacco ...

Seeding Program Will Produce Tobacco for Up To 2 Billion Sticks – The Entire Annual Cigarette Consumption of New Zealand – To Make Reduced Nicotine Content Cigarettes Readily Available at National Scale VLN ® Poised to Serve as the Foundational Cigarette for R...

VLN ® , a cigarette with 95% less nicotine than conventional cigarettes, is now available for the 75% of Colorad o smokers that are willing to switch brands to help them cut back DENVER, Feb. 07, 2023 (GLOBE NEWSWIRE) -- A new survey of 500 Colorado adults who smo...

22nd Century ( NASDAQ: XXII ) said it had acquired a privately-held UK distributor of cannabinoids RX Pharmatech for an up-front payment of $650K in cash and stock and a three-year equity earn-out based on revenue milestones. RXP’s products include CBD isolate and fin...

Immediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA 1,276 Novel Food Applications for Cannabinoid Products to Accelerate Growth in the U.K. and EU Food and Nutraceuticals Markets BUFFALO, NY, Jan. 24, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. ...

22nd Century Group ( NASDAQ: XXII ) has filed a US Drug Master File to the US FDA for cannabidiol ("CBD") active pharmaceutical ingredient ("API") from subsidiary GVB Biopharma. 22nd Century ( XXII ) and GVB also brokered an agreement with Cannabinoid API Solutions a...

BUFFALO, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced filing of a U.S. Drug Master File (DM...

Two of the Largest U.S. Convenience Store Distributors Will Support VLN® Rollout into New States and Regions Expects Multiple Retail Chain Customers of Core-Mark and Eby-Brown to Carry 22nd Century's VLN® Cigarettes Buffalo, New York--(Newsfile Corp. - January 18, 2023) - 22nd Cen...